PHARMA PULSE
Sunday, May 10, 2026
Scanned today: FierceBiotech · BioPharma Dive · Science.org · Reddit
Key advances and setbacks across late‑stage programs.
FIERCEBIOTECH · R/BIOTECH
Researchers delivered a liver‑targeted gene that produced a protein capable of degrading amyloid plaques in mouse brains, sidestepping the blood‑brain barrier. The approach could become a one‑time gene therapy for Alzheimer’s if human translation succeeds.
If efficacy translates, the therapy could redefine disease‑modifying strategies for neurodegeneration.
FIERCEBIOTECH · R/BIOTECH
A seven‑analyte panel (Hepta) is being validated to forecast patient responsiveness to GLP‑1 agonists like Ozempic and Wegovy, addressing the current trial‑and‑error prescribing pattern.
Widespread adoption could cut ineffective prescriptions and improve payer confidence.
FIERCEBIOTECH · R/BIOTECH
BeOne Medicines eliminated five early‑stage oncology assets and stopped a rheumatoid arthritis trial after interim data failed to meet endpoints, narrowing its focus to a smaller pipeline.
The pruning signals a strategic shift toward higher‑probability assets.
FIERCEBIOTECH · R/BIOTECH
Avalo reported a statistically significant, though modest, improvement in its skin‑disease indication. The result fell short of its rival program at AbbVie but spurred a pre‑emptive partnership discussion.
Positive data may attract acquisition interest despite the placebo gap.
FIERCEBIOTECH · R/BIOTECH
The company halted internal development of its IL‑2 candidate, abandoning a planned oncology indication and shelving its accelerated‑approval strategy.
The move underscores rising caution around cytokine‑based oncology platforms.
Policy shifts and agency decisions shaping the market.
FIERCEBIOTECH · R/BIOTECH
Following industry pushback, the agency agreed to revisit its earlier dismissal of the T‑cell therapy Ebvallo, which was based on a single‑arm trial design. A reversal could set a precedent for uniQure’s gene‑therapy filing.
Regulatory flexibility may revive other single‑arm cellular candidates.
FIERCEBIOTECH · R/BIOTECH
A Wall Street Journal report says the administration is moving to dismiss Commissioner Marty Makary, citing policy disagreements. The potential shake‑up adds uncertainty to ongoing drug‑approval timelines.
Stakeholders should prepare for possible delays in pending submissions.
FIERCEBIOTECH · R/BIOTECH
Legislation would prohibit the import of roughly 20,000 non‑human primates used in pre‑clinical research, potentially forcing labs to shift to alternative models.
Companies may need to invest in organ‑on‑chip or in‑silico platforms to maintain pipelines.
Capital movements reshaping the competitive landscape.
FIERCEBIOTECH · R/BIOTECH
Roche agreed to pay just over $1 billion for digital‑pathology specialist PathAI, aiming to embed AI‑driven image analysis across its diagnostic portfolio.
The deal positions Roche as a front‑runner in AI‑enabled precision medicine.
FIERCEBIOTECH · R/BIOTECH
The biotech listed on Nasdaq, raising $304 million to advance multiple autoimmune‑inflammatory candidates, including two late‑stage antibodies.
Liquidity will accelerate Phase‑3 launches and broaden its partnership options.
FIERCEBIOTECH · R/BIOTECH
The capital infusion aims to shrink the 40‑pill daily regimen for cystic fibrosis‑related exocrine pancreatic insufficiency to a three‑pill bundle.
A streamlined therapy could unlock broader payer acceptance.
FIERCEBIOTECH · R/BIOTECH
The CRO startup secured over $100 million for its “NewCo” platform and inked a strategic services agreement with global CRO ICON.
Funding will fuel rapid launch of multiple late‑stage assets.
FIERCEBIOTECH · R/BIOTECH
The British pharma secured an oligonucleotide platform from Chinese partner SiranBio to target abdominal fat, expanding its cardiometabolic pipeline.
Cross‑border collaboration underscores the growing role of nucleic‑acid therapeutics.
FIERCEBIOTECH · R/BIOTECH
The deal includes $300 million upfront and up to $2.15 billion in milestones for a mid‑phase implant that improves outcomes in retinal disease.
Eye‑care consolidation may accelerate market entry for innovative delivery platforms.
FIERCEBIOTECH · R/BIOTECH
Funding will move its myeloma candidate toward registration and gives the company runway to consider an IPO.
Robust capital suggests confidence in differentiated myeloma approaches.
Breakthroughs and investigative studies shaping tomorrow’s therapeutics.
FIERCEBIOTECH · R/BIOTECH
Scientists isolated monoclonal antibodies from vaccinated donors that block the viral fusion process, offering a therapeutic route for the recent measles resurgence.
Passive immunization may complement vaccination gaps in outbreak regions.
FIERCEBIOTECH · R/BIOTECH
Q1 earnings highlighted concrete AI use cases: target de‑risking, trial‑site selection, and real‑world evidence generation, moving beyond hype.
Quantifiable AI gains are becoming a key valuation metric for big pharma.
Financial moves, analyst outlooks, and commercial performance.
FIERCEBIOTECH · R/BIOTECH
Leerink Partners lowered its revenue expectations for the bladder‑cancer asset after Phase‑2 results fell short, widening the gap with rival Johnson & Johnson.
The downgrade pressures enGene’s near‑term cash runway.
FIERCEBIOTECH · R/BIOTECH
Top‑line results for the Duchenne muscular dystrophy program fell well below expectations, sending shares tumbling and giving Novartis a competitive edge.
Investor confidence in DMD platforms may shift toward larger incumbents.
FIERCEBIOTECH · R/BIOTECH
The insulin‑pump maker raised its full‑year outlook on strong Q1 sales, though ongoing product recalls continue to loom over the brand.
Guidance lift signals resilience despite operational setbacks.
FIERCEBIOTECH · R/BIOTECH
Two of the three liver‑focused programs from the $952 M Albireo deal were dropped, with one candidate discontinued outright.
The move highlights post‑M&A integration challenges.
Regulatory climate and legislative actions.
FIERCEBIOTECH · R/BIOTECH
The bill would ban importation of roughly 20,000 primates used annually in U.S. labs, pushing the industry toward alternative pre‑clinical models.
Regulatory bodies may see increased pressure to accept non‑animal validation.
Redditors’ take on emerging pipelines.
REDDIT · R/BIOTECH
The community highlighted a mix of mRNA, gene‑editing and AI‑driven candidates, with the top picks being a liver‑targeted RNAi for hyperlipidemia, a CRISPR‑based sickle‑cell cure, and a next‑gen GLP‑1 predictor assay.
Collective sentiment signals strong investor interest in nucleic‑acid platforms.